Jefferies Reiterates Buy Rating on Veru, Inc. (VERU), Upside DCF PT $98

Jefferies analyst Chris Howerton reiterated a Buy rating and $55.00 price target on Veru, Inc. (NASDAQ: VERU)

The analyst comments "Despite recent investor skepticism, the Ph3 CV19 results for sabizabulin published this morning addressed most concerns, in our view. Specifically: 1) patients enrolled are in fact sicker and support the higher mortality observed; 2) there was no meaningful impact of region on outcomes; and 3) baseline demographics (SoC received, BMI, etc.) were well-balanced across arms. We see today's publication as further derisking of the CV19 oppty and Reiterate BUY."

As for the upside potential, Howerton writes "US adjusted peak sales for VERU-111 in mCRPC: ~$1.2B (100% probability of success) • US adjusted peak sales for enobosarm in HR+/HER2-mBC: ~$2.2B (100% probability of success). US adjusted peak sales for Sabizabulin in CV-19: $1.3(100% probability of success). No credit to ex-US sales or other pipeline programs. DCF based PT: $98."

For an analyst ratings summary and ratings history on Veru, Inc. click here. For more ratings news on Veru, Inc. click here.

Shares of Veru, Inc. closed at $11.52 yesterday.

You May Also Be Interested In

• Oppenheime on Veru, Inc. (VERU): 'We believe this update will provide comfort'
• Flight Center Travel group Ltd. (FLT:AU) (FGETF) PT Lowered to AUD24.50 at CLSA
• Teradata (TDC) PT Lowered to $40 at Cowen